Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'

Alumis' lead drug program suffered a clinical setback Tuesday as the San Francisco biotech reported its TYK2 pill failed a mid-stage lupus study. The results put a damper on what has ...